Inositol, a simple six-carbon sugar, forms the basis of a number of important intracellular signaling molecules. Over the last 35 years, a series of biochemical and cell biological experiments have shown that lithium (Li þ ) reduces the cellular concentration of myo-inositol and as a consequence attenuates signaling within the cell. Based on these observations, inositol-depletion was proposed as a therapeutic mechanism in the treatment of bipolar mood disorder. Recent results have added significant new dimensions to the original hypothesis. However, despite a number of clinical studies, this hypothesis still remains to be either proven or refuted. In this review of our current knowledge, I will consider where the inositol-depletion hypothesis stands today and how it may be further investigated in the future.
Although known since the 19th century, in more recent years myo-inositol has been shown to form the backbone of a bewildering number of cellular compounds, a number of which act as signal molecules. Interfering with the formation of these compounds is likely to have profound effects on the cell. Remarkably, three drugs with mood stabilizing properties, lithium (Li þ ), valproic acid (VPA) and carbamazepine (CBZ) have now been shown to do precisely that. This raises the possibility that treatment of bipolar mood disorder, if not an underlying cause, involves alteration in cell signaling through inositol containing molecules. 1, 2 Although clearly a 'hot lead', current clinical data neither convincingly demonstrates inositol-depletion as the therapeutic mechanism nor eliminates it as a possibility. Here, I will discuss our current knowledge of mood stabilizers with regard to bipolar mood disorder, and consider how future work may yet point to a clinically relevant mechanism involving inositol-depletion.
Li þ and inositol-depletion
Allison and Stewart demonstrated in 1977 that Li þ treatment results in a 30% reduction in the myoinositol concentration of the rat cerebral cortex. 3 They went on to show that this is accompanied by an increase in myo-inositol-1-phosphate (InsP 1 ), 4 suggesting inhibition of the enzyme inositol-1(or 4)-monophosphatase (IMPase). Indeed, IMPase purified from a variety of sources was subsequently shown to be inhibited by Li þ with half maximal activity seen at 0.8 mM. 5, 6 Li þ acts via an uncompetitive inhibition mechanism 6 -an unusual form of inhibition caused by Li þ binding the enzyme-substrate complex. It does this by displacing a Mg 2 þ ion from the active site and prevents release of the phosphate after hydrolysis from InsP 1 . 7 This means that, in contrast to a competitive inhibitory mechanism, the higher the concentration of substrate, the greater the degree of enzyme inhibition. Such a mechanism would be ideal where greatest inhibition is only required at high substrate concentrations and has been suggested as the explanation of why the effects of Li þ are only observed in patients.
Myo-inositol is the substrate for synthesis of the membrane lipid phosphatidylinositol (PtdIns), which is then phosphorylated on the inositol carbon ring to form mono-, bis-and tris-phosphatidylinositol phosphate (PtdInsP) forms. PtdIns(4,5)P 2 is hydroylsed by the enzyme phospholipase C (PLC), whose activity is regulation by a wide range of extracellular stimuli, to release a soluble inositol tris-phosphate Ins(1,4,5)P 3 ( Figure 1 ). This is probably the most wellknown soluble inositol phosphate (InsP), and is particularly significant as it controls release of Ca 2 þ from intracellular stores. 8 Ins(1,4,5)P 3 itself is a substrate for the inositol kinases that generate a range of further phosphorylated, and even pyrophosphorylated, InsP forms. 9 It is now becoming apparent that a number of these other soluble InsPs have biological activity. 10 Ins(1,4,5)P 3 is dephosphorylated by the action of inositol phosphatases, which sequentially remove phosphate to form InsP 1 , the substrate of IMPase. Inositol-1,4 bisphosphate 1-phosphatase (IPP), which dephosphorylates Ins(1,4)P 2 , is also Li þ inhibited.
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Li þ therefore restricts recycling of myo-inositol. This restriction becomes more significant if we consider the de novo synthesis of myo-inositol, which occurs by isomerization of glucose 6-phosphate to form InP 1 by the action of the enzyme inositol synthse (known as Ino1 in yeast). As the immediate product of this reaction is InsP 1 , Li þ again blocks the final dephosphorylation step to generate myo-inositol. Li þ therefore blocks the two major intracellular routes for the production of inositol. The resulting drop in myoinositol can be overcome by myo-inositol uptake from exogenous sources, and addition of myo-inositol to the medium of growing cells is a frequent test for inositol-depletion.
VPA and inositol depletion
VPA is a widely prescribed antiepileptic drug that is increasingly being used alone, or in combination with Li þ in the treatment of bipolar disorder. 12 As seen for Li þ , chronic VPA treatment decreases the myoinositol and increases the InP 1 concentration in the rat brain. 13 In the yeast S. cerevisiae and the amobea Dictyostelium, the intracellular inositol concentration regulates expression of the ino-1 gene through a feedback mechanism and hence ino-1 expression can be used to monitor inositol. 14, 15 In both cases, Li þ and VPA increase ino-1 expression, indicating decreased inositol. This is reversed by addition of exogenous myo-inositol, indicative of inositol-depletion. In a comparable experiment, chronic Li þ treatment upregulated the inositol synthase gene IMPA1, one of two genes encoding an IMPase enzyme in the mouse hippocampus. 16 In Dictyostelium, both Li þ and VPA reduce total Ins(1,4,5)P 3 concentrations and cause similar changes in cell chemotaxis. 15, 17 Here, combining Li þ and VPA at subthreshold concentrations leads to an enhanced effect, suggesting that each drug works within the same signal transduction pathway, but on different components (Figure 1 ). In cytosolic extracts from yeast and the human brain, VPA inhibits inositol synthase/Ino1 activity and hence targets inositol synthesis. 18 Interestingly, VPA does not inhibit purified or bacterially produced inositol synthase, suggesting that either a metabolite of VPA is the true inhibitor or that VPA targets an additional protein required for inositol synthase activity.
Further evidence for an inositol-depletion mechanism for VPA action is seen in mutant studies using Dictyostelium. Ablation of the gene encoding the enzyme prolyl oligopeptidase (PO) generated cells with reduced sensitivity to Li þ . 17 When tested, these mutants were discovered to be crossresistant to VPA. These PO mutants have elevated basal concentrations of Ins(1,4,5)P 3 , suggesting that they have upregulated their InsP biosynthetic pathway. Consistent with this notion, PLC activity is unaffected in these mutants but they exhibit enhanced levels of dephosphorylation of InsP 6 to Ins(1,4,5)P 3 . The inverse relationship between PO activity and Ins(1,4,5)P3 concentration has also been shown in the astroglioma cell line U343. 19 
Mood stabilizers and neuronal growth cones
An alternative to examining inositol biochemistry is to look for common effects of mood stabilizers on cell behaviour. A useful system is to examine the behaviour of neuronal growth cones that form at the ends of developing neuronal dendrites and axons. Growth cones are motile structures that undergo chemotaxis in response to guidance cues; when they reach their target, they form the synapse. Growth cones steer by localized assembly and disassembly of both filamentous actin (F-actin) and microtubules. Migrating growth cones cycle between fast moving, elongated forms with a contracted appearance and slow moving, spread forms, which correspond to periods where cones integrate chemotactic signals from their environment and change direction. 20 In experiments using neurons of the newborn rat dorsal root ganglia (DRG), both Li þ and VPA increase the proportion of spread axonal growth cones in relation to those with a contracted form. 21 It also causes substantial growth cone spreading at therapeutic drug concentrations. The effects of Li þ , VPA and CBZ on growth cone spreading are all reversed by the addition of myo-inositol; effects not seen with epi-and scyllo-inositol isomers. 22 This indicates that these three mood stabilizers act via depletion of myoinositol. Lamotrigne, a recent addition to the repertoire of mood stabilizing drugs, however does not cause growth cone spreading. 22 PO inhibitors have the same effect as myo-inositol in reversing the effects of Li þ , VPA and CBZ. 15 This indicates that the interaction between PO and InsP metabolism is likely to be conserved in mammalian neurons and provides additional evidence to support the inositol depletion hypothesis for Li þ , VPA and CBZ action. Currently, it is unclear how CBZ affects InsP signaling.
Inositol uptake and mood stabilizers
The effectiveness of any agent causing inositoldepletion will depend on the influx from exogenous sources. For most cells, inositol is readily availablewe ingest 1 g of inositol per day in our diet and synthesize around 4 g in the kidney. Cerebrospinal fluid however contains only between 400 and 600 mM myo-inositol, a concentration significantly below that used to reverse inositol-depletion in cultured cells. 23 However, although some neuronal cell types have relatively low inositol concentrations, in general the cellular concentration of inositol within the brain is much higher, reaching 10 mM or more. This is because both neuronal and glial cell types actively import myo-inositol.
There are two myo-inositol transporters in the brain. The highest affinity transporter (Km ¼ 25-50 mM), sodium/myo-inositol transporter (SMIT), is dependent on Na þ and inhibited at reduced pH. It is present in all regions of the brain, but there are large differences in mRNA distribution and transporter activity. 24, 25 A second transporter of unrelated sequence is activated as the pH lowers, and is known as the H þ /myoinositol transporter (HMIT). 26 Following depolarization and protein kinase C (PKC) activation HMIT translocates to the plasma membrane at growth cones, leading to increased myo-inositol uptake. 27 SMIT inhibition may present an additional mechanism for inositol-depletion. In astrocyte cultures, Li þ , VPA and CBZ all reduce SMIT activity ( Figure 1 ) and mRNA concentrations. 28 This effect accumulates slowly and matches the therapeutic time course of Li þ action. The mechanism by which these drugs affect SMIT is unclear. In addition, high external inositol concentrations downregulate inositol uptake in astrocytes, 29 and has been proposed to explain the apparent mood stabilizing effects of myo-inositol when taken at high doses. 23 The mouse SMIT gene has been disrupted, but is lethal, causing death just after birth. 30 These mice show an approximately 90% reduction in myo-inositol in the fetal brain, consistent with inhibition of SMIT leading to inositol-depletion. SMIT À/À mice however show no significant loss of PdtIns, 31 arguing that inhibition of SMIT may not be a significant contributor to attenuation of InsP signaling. Based on these experiments, it has been proposed that inositol-depletion is not a significant effect in the brain. However, if these results in the fetal brain can be extrapolated to the adult brain, it remains possible that the high levels of myo-inositol in the brain serve an additional function unrelated to InsP signaling, such as osmoregulation, 32 which is biochemically compartmentalized from that utilized for cell signaling. Alternatively, but more radically, it is possible that the reduced InsP observed after Li þ treatment reduction may arise via a mechanism that bypasses PdtIns intermediates.
Alternative targets of Li
þ and VPA
A second problem for proponents of inositol-depletion is that both Li þ and VPA have other significant cellular targets. In addition to a range of signal transduction pathways that are indirectly affected by Li þ , there are a number of alternaitve direct targets now known for Li þ or VPA, but not CBZ. IMPase and IPP belong to a structurally related superfamily of phosphomonoesterase proteins that are also inhibited by Li þ . 33 Some Li þ -sensitive phosphomonoesterases, including RnPIP and the S. cerevisiae protein Hal2, dephosphorylate both 3 0 phosphoadenosine 5 0 phosphate (PAP) and PdtIns (4,5)P 2 , with, in many cases, the PAP phosphatase activity being predominant. 34 Inhibition of PAP phosphatase Li þ causes increased PAP, which is a potent inhibitor of enzymes that utilize 3 0 phosphoadensosine 5 0 phosphosulphate (PAPS), such as sulphotransferases. Loss of PAP phosphatase in yeast causes sulphur and methioinine auxotrophy, and inhibits RNA processing. 35 It is not yet known whether blocking PAP phosphatase contributes to the therapeutic effects of Li þ treatment. Li þ also inhibits the structurally unrelated protein phosphoglucomutases (PGM) in a range that matches the therapeutic dose of Li þ . 36, 37 This enzyme family, of which there are multiple genes, converts glucose 1-phosphate to the glucose 6-phosphate isomer and hence acts as an entry point into glycolysis. In fact, Li þ becomes toxic in situations that are dependent on this glucose isomerization, such as when yeast grow in galactose. 37 It will also act on other hexose sugars but often with reduced kinetics. For example, human PGM3 was originally isolated for its N-acetylglucosamine-phosphate mutase activity. 38 The significance of PGM as a therapeutic target is unknown, although it is interesting to consider what a reduction in the availability of glucose 6-phosphate may have on myo-inositol synthesis.
The major alternative to the inositol-depletion hypotheis is Li þ inhibition of glycogen synthase kinase-3 (GSK-3) kinases. 39 This serine/threonine protein kinase family is highly conserved throughout the eukaryotes, and is found as two isoforms, GSK-3a and GSK-3b, in vertebrates. 40 
GSK-3 activity has been associated with a number of neuronal effects (Figure 2 ). GSK-3 overexpression correlates with neuronal degeneration 43 and increased sensitivity to apoptotic stimuli 44, 45 in human neuroblastoma SH-SY5Y cells. b-Amyloid (Ab) treatment of rat hippocampal neurons increases GSK-3b expression and induces apoptosis, which is blocked by antisense oligonucleotides directed at GSK-3.
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Phosphorylation at its N-terminus by the enzyme PKB (also referred to as c-AKT) decreases kinase activity, whereas tyrosine phosphorylation increases its activity. 48 Both regulatory phosphorylation events have been associated with apopotosis, and Li þ 49,50 and the GSK-3 inhibitors SB216763 and SB415286 are neuroprotective. 51 GSK-3 is also involved in regulation of growth cone chemotaxis and neuronal morphology. Inactive GSK-3, phosphorylated at the N-terminus, is present in the periphery of migrating growth cones, however global application of Semaphorin 3A (Sema3A), a negative guidance cue, causes a rapid loss in GSK-3 phosphorylation and growth cone retraction. 52 Pretreatment with Li þ , SB216763 or SB415286 blocks the Sem3A response. More long-term cytoskeletal changes are seen in response to Wnt ligand mediated regulation of GSK-3. This does not involve changes in GSK-3 phosphorylation, but instead controls formation of a complex between GSK-3 and the scaffold protein Axin. When Wnt binds a receptor complex between Frizzled (Fz) and LRP 5 or 6, it mediates dissociation of GSK-3 from Axin in a process that requires the protein Dvl. 53 Wnt stimulation, or Li þ treatment, alters microtubule dynamics in neuronal growth cones and increases branching along the axon. 54 This requires both Dvl and Axin proteins and via mechanism not yet understood regulates GSK-3 phosphorylation of the microtubule binding protein, MAP1B. 55 Wnt proteins also interact with an atypical tyrosine kinase receptor, Ryk, to control neuronal out growth and axon guidance. [56] [57] [58] The relationship of this Wnt pathway to regulation of the cytoskeleton is not known, but Wnt stimulation Ryk appears to activate the Wnt-Fz pathway. 58 Altered GSK-3 activity could therefore regulate both cell number and neuronal morphology in the brain. Potentially, this could have profound effects on the complexity of neuronal interactions, although this has yet to be demonstrated. Recent results however have shown that Li þ and specific GSK-3 inhibitors cause similar changes in behaviour of mice and rats to that seen with antidepressant treatment. [59] [60] [61] Consistent with GSK-3 inhibition, the same behavioural changes are seen in GSK-3b þ /À heterozygous mice. 59 These observations indeed suggest that reduced GSK-3 activity has long-term effects on brain function and animal behaviour. Initially, VPA was reported to directly inhibit GSK-3 activity; however, this has not been substantiated by further experiments. [62] [63] [64] Instead, VPA inhibits the transcriptional repressor histone deacetylase (HDAC), and can mimic the effect of Li þ on Wnt signaling by increasing expression of b-catenin (Figure 2) , although the mechanism is via increased b-catenin expression rather than the increased protein stability that arises through GSK-3 inhibition. 63 To complicate the situation further, a number of reports point to indirect inhibition of GSK-3 activity through modulating upstream effects. 64, 65 These VPA effects, which could arise through altered gene expression, appear to be cell specific and vary between the developmental stage of the same cells. For example, VPA, or the alternative HDAC inhibitor trichostatin A, failed to increase b-catenin expression in DRG cells and had the opposite effect to Li þ on axonal branching. 15 Figure 2 GSK-3 mediated signaling in neurons. Glycogen synthase kinase 3 (GSK-3) activity can promote neuronal cell death, but is inhibited by phosphorylation from protein kinase B (PKB). This enzyme is activated by receptormediated changes in phosphatidyl 3-kinase (PI3K) activity. The repulsive neuronal guidance cue Semaphorin 3A (Sema 3A) activates GSK-3 through blocking phosphorylation to cause growth cone retraction. GSK-3 in association with Axin phosphorylates microtubule binding proteins (MAP1B and tau) to alter microtubule dynamics. It also phosphorylates b-catenin, which is degraded to prevent induction of gene expression. Association of GSK-3 with Axin is regulated via Wnt stimulation of a co-receptor complex of Frizzled (Fz) and LRP-5 or -6, and the Dvl protein. Wnt also binds to a receptor tyrosine kinase (Ryk), which is required for Wnt-Fz-LRP function.
Preclinical and clinical studies
As both Li þ and VPA have alternative cellular targets, do whole animal and clinical studies support or exclude an inositol-depletion mechanism for the action of mood stabilizers? Preclinical studies have demonstrated that Li þ inhibits IMPase in mammal brain slices. 66, 67 It should be noted that a complex pattern is found when Ins(1,4,5)P 3 concentrations are measured. Effects on Ins(1,4,5)P 3 vary between species and in some cases concentrations rise upon Li þ addition. 68, 69 This may arise through Li þ increasing neurotransmitter release and indirectly generating Ins(1,4,5)P 3 through paracrine cell stimulation. 70 Furthermore, in C6 glioma cultures, chronic VPA exposure enhances serotonin stimulated Ins(1,4,5)P 3 production due to increasing expression of the 5-HT 2A receptor. 71 Consistent with inositol-depletion, chronic exposure of animals to Li þ or VPA however leads to a decrease in inositol within certain brain regions and a build-up of InsP 1 . In addition, some Li þ effects on animal behaviour can be ascribed to inositol-depletion, such as suppression of rearing behaviour in rats, which is reversed by intracerebroventricular injection of inositol. 72, 73 In principle, it should be possible to use postmortem studies or magnetic resonance scanning (MRS) on both untreated and treated patients to establish whether altered inositol metabolism is associated with bipolar mood disorder. In practice, however, such studies have suffered from small sample sizes, uncertainty over post-mortem material and in MRS studies difficulties when resolving InsP 1 from other phosphomonoesters (PME) using 31 P-MRS or myo-inositol from InsP 1 using 1 H-MRS; 74 therefore, caution needs to be taken in interpreting results. Most studies have examined medicated patients undergoing Li þ or VPA treatment. The majority show results consistent with decreased myo-inositol or increased InsP 1 , [74] [75] [76] [77] [78] however, some find no difference. 79, 80 The failure to find differences in chronically treated patients has been interpreted as treatment leading to normalization of signaling. Changes may also reflect spatial heterogeneity in Li þ and VPA responses, and a recent study found inositol reduced by Li þ in white matter, but increased in grey matter. 81 When examined in unmedicated patients, slight elevation of myo-inositol concentration has been observed, but possibly due to small sample size, these results have yet to reach statistical significance. 78 However, in contradiction of such results, inositol and PtdInsP concentrations were found to be significantly lower in lymphocyte derived cell lines derived from bipolar patients compared to controls, 82, 83 and reduced levels of PdtIns(4,5)P 2 are seen in platelet membrane from bipolar patients. 84 The interaction between InsP signaling and PO activity presents an alternative means of examining changes in bipolar disorder. PO activity is required during normal brain function as its inhibitors enhance memory. [85] [86] [87] [88] Changes in PO activity have previously been associated with mood disorders as well as a small number of other mental illnesses. 89, 90 A recent report found that euthymic bipolar patients treated with Li þ had reduced plasma prolyl oligopeptidase activity. 91 This suggests that alterations in plasma prolyl oligopeptidase activity could lead to altered cellular concentrations of myoinositol, which can then be readjusted by Li þ , VPA or CBZ treatment.
How does inositol-depletion work?
Although observed changes in myo-inositol concentration in patients could be a suitable marker for mood stabilizer treatment, it may be a poor marker of altered InsP signaling in patients prior to treatment. This may particularly be the case if, as suggested by the SMIT gene disruption studies, high brain concentrations of myo-inositol serve other functions that mask changes in signaling. A way around this problem is to observe downstream changes that arise through changes in inositol based signaling. Current research suggests a number of processes that may significantly change as a consequence of reduced inositol concentrations. In this final section, I will consider the consequences of inositol-depletion on cell signaling (Figure 3 ) and how they may be used to observe effects in mood disorders.
Calcium signaling
Ins(1,4,5)P 3 is the most studied InsP, and is well known for its mobilization of Ca 2 þ from intracellular stores. 8 Many extracellular receptors, such as certain serotonin and muscarinic receptors, activate PLC to release from the endoplasmic reticulum, and mediates a range of signal pathways. Both Ca 2 þ and DAG stimulate protein kinase C (PKC), also a component of other signal pathways. Ins(1,4,5)P 3 is phosphorylated to form the higher order InsP (InsP 4 , InsP 5 and InsP 6 ). In yeast, the ratio of InsP 4 /InsP 5 to InsP 6 alters the activity of chromatin remodeling factors to control gene expression. InsP 6 also regulates mRNA export from the nucleus in yeast. Phosphatidyl 3-kinase (PI3k) forms PtdIns(3,4,5)P 3 , which regulates signaling enzymes such as PKB and is active during the control of chemotaxis.
generate Ins(1,4,5)P 3 .
92,93 Intracellular Ca 2 þ concentrations are clearly important for modulating neuronal activity and they change in response to many neurotransmitters. Alteration in the response and kinetics of Ca 2 þ release through changes in Ins(1,4,5)P 3 signaling would be expected to affect neuronal function. It has been suggested that direct effects on Ca 2 þ signaling would be much faster than the therapeutic time course of more than a week; however, this would depend on the time taken to reach the threshold for a biological response. Li-MRS studies indicate that although Li þ enters the brain within hours, it takes week before maximal levels are reached. 94 Direct alterations in Ca 2 þ signaling have not been examined in brains of patients with bipolar disorder; however, altered Ca 2 þ signaling in the lymphocytes of patients offers a promising lead. 95, 96 Protein kinase C (PKC) This is a family of serine/threonine protein kinases distinguished by their structure and cofactor requirements. They can be divided into three groups: conventional PKC (cPKC) enzymes, such as a, b, g forms, which require both Ca 2 þ and diacylglycerol (DAG); novel PKC (nPKC) enzymes, such as d, e, Z, y, m forms, which require only DAG; and atypical PKC (aPKC) enzymes, such as z, i, l forms, which require neither Ca 2 þ nor DAG. 97 In addition to release of soluble Ins(1,4,5)P 3 , PLC mediated hydrolysis of PdtIns(4,5)P 2 liberates DAG in the plasma membrane, it therefore generates the two cofactors required for cPKC activity. Although these are not the only requirements for PKC regulation, reduced levels of PdtIns(4,5)P 2 via inositol-depletion would be expected to attenuate cPKC activity.
Among their many functions, PKCs can facilitate neurotransmitter release via a range of mechanisms including regulating both influx and release of Ca 2 þ and presynaptic vesicle recruitment and release. 98 PKC activation requires translocation to the membrane where it interacts with the receptor for activated C-kinase-1 (RACKS-1) protein. Li þ treatment reduces this translocation, consistent with reduced generation of DAG from PdtIns(4,5)P 2 , 99 and increased association with RACK-1 has been observed in post-mortem brains from bipolar patients. 100 Chronic Li þ treatment in rats decreases both PKC activity and phosphorylation of a PKC substrate, myristoylated alanine-rich C kinase substrate (MARCKS), 101 an effect reversed by addition of myoinositol. 102, 103 This response however is complex. VPA, but not CBZ or other psychotropic drugs, also reduces PKC activity and MARCKS phosphorylation, but in this case no myo-inositol rescue was observed. 102 Both Li þ and VPA reduce the expression of MARCKS and this could account for the altered phosphorylation. Furthermore, when protein levels were examined, both Li þ and VPA reduced expression of PKCa and PKCe. 102 It is possible that these changes arise as a direct result of prolonged inactivation; however, it also raises the distinct possibility that altered PKC activity does not arise as a direct consequence of inositol depletion.
Gene expression
The therapeutic time course is more than sufficient for changes in gene expression, and there are a number of routes through which inositol-depletion could elicit such changes. Two well-characterized kinases PKC (see above) and Ca 2 þ /calmodulin kinase II (CamkII) are both known to regulate gene expression and can be affected by changes in Ca 2 þ signaling. Both Li þ and CBZ have been shown to reduce DNA binding of the transcription factor AP-1 in SH-SY5Y cells in response to carbachol. 104 These inhibitory effects involve both PKC and CamkII activity. However, as described above for PKC and MARCKS, this response is complex. It appears to not occur with VPA nor involve large changes in Ca 2 þ concentrations. In addition, as GSK-3 sits downstream of PKC in the regulation of c-jun, an AP-1 subunit, these effects could arise through a different mechanism. 105, 106 There are however alternative ways that InsP species could effect gene expression. In yeast, IP 6 affects mRNA export from the nucleus. 107 Another possibility is that higher order InsPs directly change gene promoter activity. In yeast, the genes encoding inositol synthase (ino-1) and the phosphate response gene pho5 are regulated through changes in ATPdependent chromatin remodeling complexes. [108] [109] [110] In particular, InsP 6 inhibits nucleosome mobilization by the INO80 complex leading to reduced expression of ino-1, whereas Ins(1,4,5,6)P 4 and InsP 5 species activate the SWI/SNF complex leading to increased expression of ino-1. Little is known about these effects outside yeast and they have not been examined in cells treated with Li þ or other mood stabilizers.
Cytoskeletal changes
In addition to PtdIns(4,5)P 2 , changes in other PtdInsP species would also be expected to alter cell signaling. In particular PtdIns(3,4,5)P 3 , which is generated by phosphoinostide 3 kinase (PI3 kinase) from PtdIns(4,5)P 2 , mediates translocation of a range of proteins to regions of the plasma membrane, where they activate a number of signal transduction pathways. 111 Among its functions, PtdIns(3,4,5)P 3 is involved in chemotaxis in many eukaryotic cells, 112 and it has been shown that decreasing PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 using an inactive phosphatidylinositol 4-phosphate 5-kinase, antagonises the effects of several guidance cues that induce growth cone collapse, including Sema3A. 113, 114 The discovery of neurogenesis in the adult brain opens up some interesting possibilities. Neurogenesis, albeit at a low rate, has been reported in the adult brain of rodents, primates and in the human brain. 93, 115, 116 Although discussion in the literature has centred around effects on cell number and survival, it is important to note that newly formed neurons in the mouse hippocampus possess functional, morphological and electrophysiological interactions with the surrounding cells. 117 Mood stabilizers drugs could alter the morphogenesis of these new neurons and readjust interactions, which may either restore or augment neural activity. 118 If the processes modulating chemotaxis and neuronal morphology are fully investigated, it may eventually be possible to relate morphometric differences in brain structure between bipolar mood disorder patients and unaffected individuals 119 to changes in phosphatidylinositol signaling.
Concluding remarks
Since its conception, in vitro and cell culture based experiments have continued to support the inositoldepletion hypothesis, and in fact it can explain the effects of a number of, but probably not all, mood stabilizers. The problem lies with translating these observations into clinical studies. As discussed there are a number of problems. GSK-3 is an alternative Li þ target that is inhibited at therapeutic concentrations and affects neuronal development, cell biology and animal behaviour. However, there is less evidence to directly associate GSK-3 with bipolar mood disorder than for inositol-depletion. This may not be the case for other mental disorders, and for example, a recent study suggests a link to schizophrenia. 120 It is also possible that the therapeutic effect of Li þ and VPA arises through a combination of both GSK-3 and inositol-depletion effects. No clinical trials using specific IMPase or GSK-3 inhibitors have been reported.
An additional problem is the difficulty observing inositol-depletion in the clinical context. Changes could be very localized with the brain, and perhaps large changes only occur in specific regions; other regions could respond differently and hence confound studies. Furthermore, monitoring total inositol, or InsP, may be misleading if changes in InsP signaling are masked by high concentrations of myoinositol with additional, nonsignaling functions. In this case, different biomarkers are required. This could take the form of other compounds detectable by MRS 74 or, as discussed, detection of downstream effects. Finally, it is often assumed that mood stabilizers target the causes of the disorder, but this does not have to be the case. Mood stabilizer therapy could cause neural changes in bipolar disorder patients, such as depressed signaling, increased cell survival or altered neuronal connectivity, which make compensatory changes rather than reverse the original biological lesion. In this case, the biochemical basis of the bipolar disorder therapy may be completely different from that of its origins. This would mean that while it would be possible to follow treatment through monitoring altered inositol concentrations or downstream changes, alternative means may be required for diagnosis upon initial presentation.
All of these problems have as yet prevented complete testing of inositol-depletion hypothesis and it is still impossible to draw conclusions to its clinical relevance. That said, the hypothesis remains viable and new discoveries, such as inositol-depletion effects of other mood stabilizers, the role of SMIT and the intriguing association PO activity, have augmented the hypothesis since its original inception. Continued work at the basic, preclinical and clinical level may yet establish whether changes in InsP signaling form the basis of mood stabilizer therapy and perhaps the origins of bipolar disorder.
